GlassScriptPhysician profile
Mohamad Mouchli
NPI 1821324179
$1,288.04
in general payments reported to CMS, 2019-2025
22 companies · $304 in 2025
The $304 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2021: $130 · 2022: $293 · 2023: $113 · 2024: $295 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $712.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $442.45 | 2021-2025 | |
| Covidien LP | $152.72 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $93.03 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $76.74 | 2021-2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.02 | 2022-2023 | Xifaxan, Plenvu |
| Merck Sharp & Dohme LLC | $49.33 | 2022-2023 | Dificid |
| Ardelyx, INC. | $42.24 | 2023-2024 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $41.05 | 2024-2025 | Entyvio |
| Celgene Corporation | $34.60 | 2021-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $31.65 | 2024-2025 | Zenpep |
| Vibrant Gastro, INC. | $31.32 | 2024 | Vibrant Starter Kit |
| Madrigal Pharmaceuticals | $31.26 | 2025 | Rezdiffra |
| Pfizer INC. | $29.82 | 2024 | |
| Genzyme Corporation | $27.93 | 2024 | |
| Ferring Pharmaceuticals INC. | $23.89 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Laborie Medical Technologies Corp. | $23.72 | 2024 | |
| Intercept Pharmaceuticals, INC. | $16.98 | 2022 | |
| Medtronic, INC. | $16.28 | 2024 | Gi Genius |
| Gilead Sciences, INC. | $15.19 | 2021 | |
| Celltrion USA INC. | $14.39 | 2024 | Vegzelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.02 | 2023 | Cyltezo |
| Phathom Pharmaceuticals, INC. | $5.41 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamad Mouchli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.